Revista Colombiana de Reumatologia最新文献_第9页

The lung as a target and as an initiator of rheumatoid arthritis-associated immunity: Implications for interstitial lung disease 肺是类风湿性关节炎相关免疫的目标和启动器：对间质性肺病的影响

Revista Colombiana de Reumatologia Pub Date : 2024-04-01 DOI: 10.1016/j.rcreu.2023.09.006

Malena Loberg Haarhaus, Lars Klareskog

{"title":"The lung as a target and as an initiator of rheumatoid arthritis-associated immunity: Implications for interstitial lung disease","authors":"Malena Loberg Haarhaus, Lars Klareskog","doi":"10.1016/j.rcreu.2023.09.006","DOIUrl":"10.1016/j.rcreu.2023.09.006","url":null,"abstract":"<div><p>Interstitial lung disease (ILD) is a serious extra-articular co-morbidity in rheumatoid arthritis (RA) patients and accounts for a substantial part of the increased mortality in RA. In this review, we describe how environmental and lifestyle factors interact with genetic variants in the HLA genetic locus in triggering RA-specific antibodies against post-translationally modified, mainly citrullinated proteins (ACPA), which are associated with an increased risk of ILD. The same environmental risk factors, i.e. exposure to noxious agents such as smoke to the lungs contribute additionally to the emergence of RA ILD as does long-lasting high disease activity and an additional ILD-specific genetic risk variant related to mucus formation (MUC5B). Options for prevention and therapy of RA ILD resulting from this so far incomplete knowledge of its pathophysiology are expanding. The most obvious option is to address modifiable environmental risk factors, such as smoking and exposure to other noxious agents affecting the lungs. The second option is to reduce the inflammatory activity of RA; here different anti-rheumatic therapies appear to have differential effects on ILD development. The third and novel option is to use anti-fibrotic therapy which may reduce the development of RA ILD but has not yet been shown to revert existing fibrosis. The main conclusion concerning the clinical handling of RA ILD is therefore an early awareness of the risk for RA ILD combined with active measures to reduce modifiable environmental/lifestyle factors and use optimal anti-rheumatic therapies for early and sustained reduction of disease activity. These actions should be combined with a preparedness to use anti-fibrotic therapy for patients at high risk for ILD despite previous risk reduction efforts.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 ","pages":"Pages S74-S81"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139540635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myositis-associated interstitial lung disease 肌炎相关间质性肺病

Revista Colombiana de Reumatologia Pub Date : 2024-04-01 DOI: 10.1016/j.rcreu.2023.09.003

Siamak Moghadam-Kia, Chester V. Oddis

{"title":"Myositis-associated interstitial lung disease","authors":"Siamak Moghadam-Kia, Chester V. Oddis","doi":"10.1016/j.rcreu.2023.09.003","DOIUrl":"https://doi.org/10.1016/j.rcreu.2023.09.003","url":null,"abstract":"<div><h3>Introduction/Objective</h3><p>To review the epidemiology, general clinical aspects and diagnosis, impact on morbidity and mortality, and general treatment approaches for myositis-associated ILD.</p></div><div><h3>Materials and methods</h3><p>The relevant literature was reviewed.</p></div><div><h3>Results</h3><p>The clinical, radiographic, and histopathological features of interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) are similar to idiopathic ILD. Patients with a known diagnosis of myositis require prompt clinical evaluation including the determination of myositis-associated autoantibodies. Patients possessing autoantibodies associated with ILD or those with any pulmonary symptoms should undergo a pulmonary function test and high-resolution CT (HRCT) scanning of their lungs.</p></div><div><h3>Conclusion</h3><p>Despite the lack of placebo-controlled trials, systemic glucocorticoids are considered the mainstay of initial treatment of myositis-associated ILD. Glucocorticoid-sparing agents are often concomitantly administered, particularly in patients with severe disease. The first-line conventional immunosuppressive drugs include either mycophenolate mofetil or azathioprine. If these agents fail or if the pulmonary features are severe or rapidly progressive, then more aggressive immunosuppressive or immunomodulatory therapy including cyclophosphamide, tacrolimus<span> or cyclosporine, rituximab, IVIg, or tofacitinib can be considered. Further investigations are required to assess the role of novel therapies in the treatment of myositis-associated ILD.</span></p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 ","pages":"Pages S154-S165"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140344055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of screening, treatment, and next steps in research in rheumatoid arthritis interstitial lung disease 类风湿性关节炎间质性肺病的筛查、治疗和下一步研究综述

Revista Colombiana de Reumatologia Pub Date : 2024-04-01 DOI: 10.1016/j.rcreu.2023.07.002

Scott M. Matson , Joyce S. Lee

引用次数: 0

Development of an ultrasound set for early diagnosis of rheumatoid arthritis: First steps 用于类风湿性关节炎早期诊断的超声装置的开发：第一步

Revista Colombiana de Reumatologia Pub Date : 2024-04-01 DOI: 10.1016/j.rcreu.2023.02.009

Ben Abdelghani Kawther , Miladi Saoussen , Mahmoud Ines , Ajlani Houda , Bahiri Rachid , Haddouche Assia , Harifi Ghita , Slimani Samy , Laatar Ahmed

{"title":"Development of an ultrasound set for early diagnosis of rheumatoid arthritis: First steps","authors":"Ben Abdelghani Kawther , Miladi Saoussen , Mahmoud Ines , Ajlani Houda , Bahiri Rachid , Haddouche Assia , Harifi Ghita , Slimani Samy , Laatar Ahmed","doi":"10.1016/j.rcreu.2023.02.009","DOIUrl":"10.1016/j.rcreu.2023.02.009","url":null,"abstract":"<div><h3>Introduction/Objective</h3><p>Early diagnosis of rheumatoid arthritis (RA) can improve the prognosis of the disease by reducing joint destruction and achieving a better rate of remission. Musculoskeletal ultrasound (US) has become a potent tool to detect synovitis and erosions. However, until now, there has been a lack of consensus on the US scoring system to help in diagnosing RA early. The purpose of our study was to elaborate a US set suitable for classifying RA patients with inflammatory arthralgia or expressing synovitis and who did not satisfy ACR/EULAR criteria, called “USSRA” (UltraSound Set for Rheumatoid Arthritis).</p></div><div><h3>Materials and methods</h3><p>A multistep study was conducted. A preliminary set of joints, tendons, and erosions to include in the USSRA were identified through a deep literature screening. The final step of this study was the validation of the final set by international experts in US using a Delphi process.</p></div><div><h3>Results</h3><p>The preliminary set included 20 joints, 16 tendons, and 8 erosion sites for assessment. After the Delphi process, the changes were to add an assessment of two additional wrist joints and remove one. As for the tendons, two sites were removed from the final set. No changes were proposed for the section erosions. The elementary lesions and scoring system were clarified. The final USSRA forms include 18 joints, 12 tendons, and 8 sites of erosion.</p></div><div><h3>Conclusion</h3><p>The USSRA is a novel diagnostic tool proposed for detecting early RA in routine practice. The next step will be to assess the reliability of this set in a patient-based exercise.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 2","pages":"Pages 178-184"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41609672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complicación hematológica con impacto pulmonar en una paciente con síndrome de Sjögren 干燥综合征患者肺部撞击的血液学并发症

Revista Colombiana de Reumatologia Pub Date : 2024-04-01 DOI: 10.1016/j.rcreu.2023.02.006

Laura Gallego , Jhon Buitrago , Diana Guavita-Navarro , Jairo Cajamarca-Barón , Ana María Arredondo , José Fernando Polo Nieto , Juan Pablo Castañeda-González , Alejandro Escobar

{"title":"Complicación hematológica con impacto pulmonar en una paciente con síndrome de Sjögren","authors":"Laura Gallego , Jhon Buitrago , Diana Guavita-Navarro , Jairo Cajamarca-Barón , Ana María Arredondo , José Fernando Polo Nieto , Juan Pablo Castañeda-González , Alejandro Escobar","doi":"10.1016/j.rcreu.2023.02.006","DOIUrl":"10.1016/j.rcreu.2023.02.006","url":null,"abstract":"<div><p>Sjögren's Syndrome (SS) is an autoimmune pathology with glandular and/or extraglandular compromise, secondary to the infiltration of lymphoid cells. The clinical course varies depending on genetic susceptibility, comorbidities, patient's age, and environmental risk factors. Lymphoid proliferation and differentiation are key factors in the progression of SS to haematological malignancies or amyloidosis. Amyloidosis is a secondary entity to the aberrant accumulation of soluble plasma proteins, derived from chronic infectious, inflammatory, neoplastic and haematolymphoid processes. The clinical manifestations vary and depend on the constitutive protein and the age of the patient; and may have glandular or extraglandular, local, or systemic compromise. Among the affected organs, pulmonary involvement poses a diagnostic and therapeutic challenge due to its variable course and clinical manifestation. The following is a case report of a woman over 70 years old, with SS and amyloidosis with glandular and extra glandular manifestations at pulmonary level.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 2","pages":"Pages 259-263"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49565653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is it possible to optimize biologic therapy in patients with psoriasis? 牛皮癣患者是否有可能优化生物治疗?

Revista Colombiana de Reumatologia Pub Date : 2024-04-01 DOI: 10.1016/j.rcreu.2022.10.002

Ángela María Londoño-García , María Fernanda Suárez-Giraldo , Lina María Colmenares-Roldán , Juliana Madrigal-Cadavid , Jorge Estrada , Paulo Giraldo , Daniel Jaramillo-Arroyave

{"title":"Is it possible to optimize biologic therapy in patients with psoriasis?","authors":"Ángela María Londoño-García , María Fernanda Suárez-Giraldo , Lina María Colmenares-Roldán , Juliana Madrigal-Cadavid , Jorge Estrada , Paulo Giraldo , Daniel Jaramillo-Arroyave","doi":"10.1016/j.rcreu.2022.10.002","DOIUrl":"10.1016/j.rcreu.2022.10.002","url":null,"abstract":"<div><h3>Introduction/Objective</h3><p>The purpose of this study was to evaluate patients in clinical remission of psoriasis for at least for one year, who maintained therapeutic goals after initiating optimization of biologic therapy.</p></div><div><h3>Materials and methods</h3><p>A descriptive, observational study was conducted on patients with a diagnosis of moderate–severe psoriasis in treatment with biologic therapy who were started on optimization of biologic therapy.</p></div><div><h3>Results</h3><p><span>A total of 29 patients started therapeutic optimization, of these, 27 patients were in the target range with absolute PASI less than 3. Only one patient failed therapeutic optimization with final PASI 3.6 and there was a case of a patient who lost continuity of management due to an accident and had a final PASI 3.8. Most of the patients were male, with an average age of 53 years, married, employed, residing in urban areas, with psoriasis of more than ten years of evolution, without associated morbidities, and without previous biologic treatment, the most frequently used being etanercept and </span>adalimumab.</p></div><div><h3>Conclusion</h3><p>Optimizing biologic therapy in patients with moderate–severe psoriasis may be viable. We seek to share this experience to propose a protocol to reduce the possibility of adverse events due to the prolonged use of this type of therapy, preserving clinical response and reducing costs to the health system.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 2","pages":"Pages 166-170"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48121994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measurement of health-related quality of life in patients with interstitial lung disease and autoimmune diseases 测量间质性肺病和自身免疫性疾病患者的健康相关生活质量

Revista Colombiana de Reumatologia Pub Date : 2024-04-01 DOI: 10.1016/j.rcreu.2023.08.005

Claudia Mora , Alirio Rodrigo Bastidas Goyes , Lina Paola Fajardo Muriel , Cristian Felipe Rodríguez Yasno

{"title":"Measurement of health-related quality of life in patients with interstitial lung disease and autoimmune diseases","authors":"Claudia Mora , Alirio Rodrigo Bastidas Goyes , Lina Paola Fajardo Muriel , Cristian Felipe Rodríguez Yasno","doi":"10.1016/j.rcreu.2023.08.005","DOIUrl":"10.1016/j.rcreu.2023.08.005","url":null,"abstract":"<div><p><span>Autoimmune diseases comprise a wide and diverse group of diseases, each with its own specific complications, and with common complications such as pulmonary involvement. Lung involvement is extensive and one of its complications is interstitial lung disease, which varies widely within each of the autoimmune diseases. Health-related </span>quality of life<span> is defined as all those aspects that reflect the impact of the disease and the perception of disability and daily functionality of the patient. Even though this concept is subjective, health researchers have sought to define it to serve as a tool in the evaluation of interventions in subjects with different types of pathologies, so much so that it has become a main outcome in program evaluation and clinical research. To date, we are not aware of tools designed with the objective of measuring quality of life specifically in lung involvement due to interstitial lung disease related to autoimmune diseases. The objective of this review will be to further explore the available information on the measurement of quality of life in these patients.</span></p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 ","pages":"Pages S67-S73"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135510586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A woman with fever, arthralgia, and chronic urticaria 发烧、关节痛和慢性荨麻疹的妇女

Revista Colombiana de Reumatologia Pub Date : 2024-01-01 DOI: 10.1016/j.rcreu.2022.06.002

Edwin Uriel Suárez , Teresa Arquero , Fernando Tornero , Sheila Recuero

引用次数: 0

Enfermedad pulmonar intersticial severa en una paciente con síndrome antisintetasa por anticuerpos anti PL-7 抗PL-7抗体抗合成酶综合征患者严重间质性肺疾病

Revista Colombiana de Reumatologia Pub Date : 2024-01-01 DOI: 10.1016/j.rcreu.2022.04.003

Sebastián Molina-Ríos , Gerardo Quintana-López

引用次数: 0

Recomendaciones en la intervención de pacientes con enfermedades reumatológicas por telemedicina en Colombia 哥伦比亚远程医疗对风湿性疾病患者干预的建议

Revista Colombiana de Reumatologia Pub Date : 2024-01-01 DOI: 10.1016/j.rcreu.2022.06.003

Andres Hormaza Jaramillo , Ana Arredondo , Elias Forero , Sebastian Herrera , Carlos Ochoa , Álvaro Arbeláez-Cortés , Andres Ricardo Fernández Aldana , Andrea Rodríguez

{"title":"Recomendaciones en la intervención de pacientes con enfermedades reumatológicas por telemedicina en Colombia","authors":"Andres Hormaza Jaramillo , Ana Arredondo , Elias Forero , Sebastian Herrera , Carlos Ochoa , Álvaro Arbeláez-Cortés , Andres Ricardo Fernández Aldana , Andrea Rodríguez","doi":"10.1016/j.rcreu.2022.06.003","DOIUrl":"10.1016/j.rcreu.2022.06.003","url":null,"abstract":"<div><h3>Introduction</h3><p>Telemedicine, defined as the provision of remote health services by health professionals using Information and Communication Technologies, has been adopted in healthcare in Colombia.</p></div><div><h3>Objective</h3><p>To establish recommendations for the implementation and management of telemedicine in clinical practice for rheumatological diseases in Colombia.</p></div><div><h3>Materials and methods</h3><p>The recommendations were made in 3 phases. Phase 1 was based on an extended review and a systematic review of the literature. Phase 2 consisted of the selection of attributes and components based on the extended review to delimit the framework of the recommendations using the Delphi method. In phase 3, a group of experts, based on the systematic review, the selected attributes and components, and individual experience made recommendations through a nominal group.</p></div><div><h3>Results</h3><p>The framework of recommendations comprised 9 attributes and 26 components. A group of 7 rheumatologists in 4 cities of the country was formed. The nominal group drafted the final recommendations through 3 rounds according to the recommendations with a high priority rating.</p></div><div><h3>Conclusions</h3><p>This document contains recommendations for effective telemedicine healthcare for rheumatological diseases in Colombia. To establish effective telemedicine healthcare, it is necessary to evaluate different possible forms of care, the convenience of using telemedicine according to the clinical-cultural and sociodemographic profile of the patient, the access and implementation capacity of the different technological tools, and the exhaustive analysis of the barriers and facilitators to its adoption.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 1","pages":"Pages 68-79"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43960123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0